首页 > 文献资料
-
人脑胶质瘤Fas和Fas Ligand的表达
目的探讨Fas受体配体系统在胶质瘤凋亡调变中的作用和意义. 方法应用免疫组织化学技术对34例胶质瘤中Fas和Fas Ligand的表达及其意义进行了研究.其中低恶性胶质瘤18例,高恶性16例. 结果 Fas在部分胶质瘤中有表达,其在高分化的Ⅰ～Ⅱ级胶质瘤的免疫反应阳性率明显低于Ⅲ～Ⅳ级胶质瘤(P＜0.01).FasL在各型胶质瘤中均有表达,其表达强度与胶质瘤的良、恶性程度无明显相关(P>0.05). 结论 Fas-FasL系统在胶质瘤凋亡调变的过程中可能起较重要的作用,Fas可辅助临床判断胶质瘤的良、恶性程度.
-
PTA1配体表达的免疫组化研究
INTRODUCTION T lineage specific activation antigen 1 (TLiSA1), first reported by Burns in 1985[1], was renamed PTA1 in 1989 because of its expression on platelets as well[2]. Since 1985, a lot of investigations have been done on PTA1 expression, its functions and its relationship with diseases. PTA1, mainly expressed on activated T cells, platelets and megakaryocytes lineage, was involved in signal transduction of T cell activation and differentiation as well as platelet activation and aggregation. PTA1 mAb (Leo-A1) was found to stimulate activation and aggregation of platelets and inhibit differentiation of CTL.
